Expression of KLRG1 on subpopulations of lymphocytes in the peripheral blood of patients with locally advanced nasopharyngeal carcinoma and prognostic analysis

We aimed to investigate the relationship between the expression of killer cell lectin like receptor G1 (KLRG1) in peripheral blood lymphocytes, and the clinical characteristics and prognosis in patients with locally advanced nasopharyngeal carcinoma (NPC), and to dynamically evaluate the changes of KLRG1 expression after treatment.

[1]  Yanchun Peng,et al.  Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma , 2021, Chinese medical journal.

[2]  Hung-Ming Wang,et al.  Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial , 2021, Nature Medicine.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Fenghua Wang,et al.  Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Yanchun Peng,et al.  Expression and Clinical Significance of KLRG1 and 2B4 on T Cells in the Peripheral Blood and Tumour of Patients with Cervical Cancer , 2021, Immunological investigations.

[6]  É. Vivier,et al.  Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers , 2021, Oncoimmunology.

[7]  D. Planchard,et al.  Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy , 2020, Clinical Cancer Research.

[8]  S. M. Toor,et al.  Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer , 2020, Cancer Immunology, Immunotherapy.

[9]  B. Goh,et al.  Elevated IL18 levels in Nasopharyngeal carcinoma induced PD-1 expression on NK cells in TILS leading to poor prognosis. , 2020, Oral oncology.

[10]  G. Ahlenstiel,et al.  KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. , 2019, Journal of hepatology.

[11]  A. Rotte,et al.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of experimental & clinical cancer research : CR.

[12]  B. Becher,et al.  CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo , 2019, PLoS pathogens.

[13]  S. Kong,et al.  Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models , 2019, Oncotarget.

[14]  Jun Ma,et al.  Nasopharyngeal carcinoma , 2019, The Lancet.

[15]  Xu-hui Liu,et al.  The Role of KLRG1 in Human CD4+ T-Cell Immunity Against Tuberculosis , 2018, The Journal of infectious diseases.

[16]  S. H. van der Burg,et al.  Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients , 2016, Oncoimmunology.

[17]  A. Lanna,et al.  Senescence of T Lymphocytes: Implications for Enhancing Human Immunity. , 2016, Trends in immunology.

[18]  K. Tao,et al.  KLRG1 restricts memory T cell antitumor immunity , 2016, Oncotarget.

[19]  J. Chiang,et al.  Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer , 2015, Scientific Reports.

[20]  George F. Murphy,et al.  Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.

[21]  S. H. van der Burg,et al.  Consensus nomenclature for CD 8 T cell phenotypes in cancer , 2015 .

[22]  S. Sarkar,et al.  Early CD8 T-cell memory precursors and terminal effectors exhibit equipotent in vivo degranulation , 2014, Cellular and Molecular Immunology.

[23]  E. Demicco,et al.  Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. , 2014, Cancer research.

[24]  J. Eloy,et al.  Nasopharyngeal squamous cell carcinoma: a comparative analysis of keratinizing and nonkeratinizing subtypes , 2014, International forum of allergy & rhinology.

[25]  J. Moorman,et al.  KLRG1 Negatively Regulates Natural Killer Cell Functions through the Akt Pathway in Individuals with Chronic Hepatitis C Virus Infection , 2013, Journal of Virology.

[26]  T. Waldmann,et al.  Superior T memory stem cell persistence supports long-lived T cell memory. , 2013, The Journal of clinical investigation.

[27]  H. Pircher,et al.  Killer Cell Lectin-Like Receptor G1 Deficiency Significantly Enhances Survival after Mycobacterium tuberculosis Infection , 2013, Infection and Immunity.

[28]  Z. Lijun,et al.  EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. , 2009, Cancer research.

[29]  S. J. Griffiths,et al.  KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. , 2009, Blood.

[30]  H. Pircher,et al.  Interaction of KLRG1 with E‐cadherin: New functional and structural insights , 2008, European journal of immunology.

[31]  H. Pircher,et al.  Tumor-Associated E-Cadherin Mutations Affect Binding to the Killer Cell Lectin-Like Receptor G1 in Humans1 , 2007, The Journal of Immunology.

[32]  R. Ferris,et al.  Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.

[33]  D. Voehringer,et al.  Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). , 2002, Blood.